PRIME designation granted based on clinical data from ongoing Phase 1/2 trial of AAV-RPGR AAV-RPGR is the only XLRP treatment in development to be awarded PRIME designation LONDON and NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc  (Nasdaq: MGTX), a vertically integrated,

LONDON and NEW YORK , Feb. 24, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes , Ph.D., president and chief executive officer, will present at the Cowen and Company 40th Annual Health